Convatec boosts outlook after strong year, shares spark
By Abigail Townsend
Date: Tuesday 24 Feb 2026
(Sharecast News) - Shares in Convatec Group sparked in early trading on Monday, after the medical products business boosted medium-term guidance following a jump in annual sales and earnings.
The blue chip, which specialises in advanced wound management alongside ostomy, continence and infusion care, saw adjusted revenues rise 5% to $2.4bn on a constant currency basis in the year to December end. Operating profits were 10.2% stronger on the same basis at $544m.
Convatec said it had seen organic growth across all categories, boosted by new product launches and improvements in the operating margin.
Jonny Mason, chief executive, called it a strong performance.
"Convatec performed strongly in 2025, demonstrating further resilient growth," he said. "Looking ahead, we are increasing our medium-term revenue growth target to 6% to 8% from 2027. This acceleration follows the successful implementation of our strategy and is underpinned by our rich innovation pipeline."
Convatec had previously forecast medium-term organic revenue growth of between 5% and 7%.
As at 0830 GMT, the stock was up 9% at 247p.
Looking to the current year, the firm said revenue growth would likely be weighed to the second half, but reiterated guidance for double digit adjusted EPS growth.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN